VEGFD and chronic kidney disease: During the screening, three (3/24, 12.5%) patients in the VEGF-D group and two (2/6, 33.3%) patients in the control group presented with reduced kidney function (eGFR < 45 mL/min/1.73 m2); further development of chronic kidney disease with a severely decreased eGFR (<30 mL/min/1.73 m2) was encountered in four (4/24, 16.7%) patients in the VEGF-D group (2.9 per 100 patient-years) and one (1/6, 16.7%) patient in the control group (3.3 per 100 patient-years) (P = 1.00).